Deals channel feed – Endpoints News

Deals channel feed

Former CEO Anne Wojcicki wins bid for 23andMe

Yesterday

CureVac CEO on BioNTech deal: Come together 'rather than fighting each other in court'

2 days ago

BioNTech to acquire CureVac in all-stock deal valued at $1.25B

3 days ago

Updated: Novo makes another cardiometabolic deal focused on oral medicines

4 days ago

BMS’ RayzeBio inks radiopharma deal in prostate cancer for $350M upfront

4 days ago

At a crossroads, biotechs are passing on reverse mergers in 2025

Last week

Anne Wojcicki and Regeneron set to duke it out in restarted 23andMe auction

Last week

Lilly makes a move for long-acting incretins in tech deal with Swedish biotech

Last week

Agenus quickly exits CDMO business by selling assets to Zydus for $75M upfront

Last week

BioNTech presents impressive early data for PD-L1xVEGF in mesothelioma

Last week

Pyx Health buys FarmboxRx to reach more Medicaid and Medicare members

Last week

Regeneron makes $80M obesity deal with Hansoh

Last week

Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

Last week

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

Last week

As a challenging first half nears a close, biopharma uncertainty persists

3 weeks ago

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

3 weeks ago

Post-Hoc Live: Is biotech sentiment really as bad as it seems?

3 weeks ago

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

3 weeks ago

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

3 weeks ago

Biogen taps City Therapeutics in RNAi deal worth up to $1B

3 weeks ago

Blackstone's GRIN inks epilepsy licensing deal with Angelini, closes $140M Series D

3 weeks ago

TCG's R&D venture team makes a T cell engager deal with Shanghai biotech

3 weeks ago

Updated: Hinge Health jumped 18% on its first day as the digital health IPO market reawakens

4 weeks ago

Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen

4 weeks ago

12 3 4 Next page Last page